Symbicort Sales Data
| Rank 34 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Symbicort U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 34 ( 3) |
$376,822 | 10.70% | 2,210 | -4.45% |
| Q4 2012 | 37 (6) |
$340,401 | 10.64% | 2,313 | 12.94% |
| Q3 2012 | 43 (3) |
$307,678 | 4.37% | 2,048 | 6.95% |
| Q2 2012 | 46 (5) |
$294,803 | 1.42% | 1,915 | 3.51% |
| Q1 2012 | 51 (5) |
$290,669 | 8.71% | 1,850 | 5.59% |
| Q4 2011 | 56 (8) |
$267,373 | 11.05% | 1,752 | 17.58% |
| Q3 2011 | 64 ( 4) |
$240,761 | -4.65% | 1,490 | 0.27% |
| Q2 2011 | 60 (2) |
$252,502 | 0.64% | 1,486 | 0.41% |
| Q1 2011 | 62 | $250,905 |  |
1,480 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| February 19, 2010 | FDA Issues Warning On 4 Widely-Used Asthma Drugs |
| February 18, 2010 | FDA Issues Warning on Key Asthma Drugs |
| February 9, 2009 | Inhaled Corticosteroids Boost Pneumonia Risk in COPD |
| December 12, 2008 | Allergists Respond to FDA Committee Recommendation on Asthma Medication, Encourage Patients with Questions to Contact Physicians |
| December 12, 2008 | AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on Symbicort |
| December 11, 2008 | FDA Panel Mulls Safety of Asthma Meds |
